GW Pharmaceuticals (NASDAQ:GWPH) Announces ‘positive’ results of Phase 3 clinical trial: Halliburton Company …

GW Pharmaceuticals plc (NASDAQ:GWPH) traded 3.34 Million shares on last trading day with closing price of $126.06. Company gross margin stands at 81.60% whereas its return on investment (ROI) is -18.10%. Stock value has moved between $35.81 – 111.56 in last one year. Analyst’s mean target price for GW Pharmaceuticals plc (NASDAQ:GWPH) while analysts mean recommendation is 2.10. GWPH EPS growth this year and EPS growth next year is -159.60%, -27.90% respectively.

GW Pharmaceuticals plc (NASDAQ:GWPH) announces positive results of the second randomized, double-blind, placebo-controlled Phase 3 clinical trial of its investigational medicine Epidiolex (cannabidiol or CBD) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy. In this trial, Epidiolex, when added to the patient’s current treatment, achieved the primary endpoint for both dose levels with high statistical significance. During the treatment period, patients taking

... read more at: http://www.benchmarkmonitor.com/gw-pharmaceuticals-nasdaqgwph-announces-positive-results-of-phase-3-clinical-trial-halliburton-company-nysehal-baker-hughes-incorporated-nysebhi-alibaba-group-nysebaba/1895863/

by